We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · September 22, 2022

Efficacy of the Anti-C5a Antibody Vilobelimab in Critically Ill Patients With COVID-19 Receiving Invasive Mechanical Ventilation

The Lancet Respiratory Medicine

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Respiratory Medicine
Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
Lancet Respir Med 2022 Sep 07;[EPub Ahead of Print], APJ Vlaar, M Witzenrath, P van Paassen, LMA Heunks, B Mourvillier, S de Bruin, EHT Lim, MC Brouwer, PR Tuinman, JFK Saraiva, G Marx, SM Lobo, R Boldo, JA Simon-Campos, AD Cornet, A Grebenyuk, JM Engelbrecht, M Mukansi, PG Jorens, R Zerbib, S Rückinger, K Pilz, R Guo, D van de Beek, NC Riedemann

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading